January 31, 2017
Ipsen buys gastrointestinal-focused-portfolio Italian company
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
Pharmaceuticals, Biotechnology and Life Sciences
Ipsen has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future.
Ipsen has acquired global oncology assets from Merrimack Pharmaceuticals. This acquisition includes Merrimack’s key marketed product Onivyde (irinotecan liposome injection)…
Exelixis and Ipsen have signed an amendment to the exclusive collaboration and licensing agreement for the commercialization and continued development…
French drugmaker Ipsen said on Monday that Claude Bertrand, Executive Vice President, R&D, Chief Scientific Officer, will step down in January…
Ipsen and its partner Exelixis today announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).